Clinical impact of anti-thymocyte globulin on survival and graft-versus-host disease in patients undergoing human leukocyte antigen mismatched allogeneic stem cell transplantation
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Rabbit anti-thymocyte globulin (ATG) is usually incorporated in hematopoietic stem cell transplantation (HSCT) to reduce the incidence of graft-versus-host disease (GVHD). This study aimed to find optimal ATG doses in patients undergoing human leukocyte antigen (HLA)-mismatched allogeneic HSCT. Methods: We retrospectively collected medical records from 352 consecutive patients with acute myeloid leukemia (n = 214), acute lymphoblastic leukemia (n = 62), or myelodysplastic syndrome (n = 76) in eight centers of Korea between 2005 and 2015. All patients received busulfan-based conditioning without total body irradiation (TBI) and received stem cells from HLA-mismatched donors. Results: In the current study, 5-year overall survival rates of patients receiving low to medium doses of ATG (2.5 to 7.5 mg/kg) were higher than those receiving other doses of ATG (hazard ratio [HR], 0.528; 95% confidence interval [CI], 0.311 to 0.897; p = 0.018). The incidence rates of extensive chronic GVHD (ecGVHD) after administration of low to medium doses of ATG were lower than those after other doses of ATG (HR, 0.447; 95% CI, 0.224 ton 0.889; p = 0.022). Conclusions: The low to medium doses of ATG may be associated with improving survival outcomes and reducing incidence of ecGVHD without enhancing the chances of relapse in patients with acute leukemia or myelodysplastic syndrome undergoing non-TBI-based HLA-mismatched allogeneic HSCT.
Abstract
Background/Aims: Rabbit anti-thymocyte globulin (ATG) is usually incorporated in hematopoietic stem cell transplantation (HSCT) to reduce the incidence of graft-versus-host disease (GVHD). This study aimed to find optimal ATG doses in patients undergoing human leukocyte antigen (HLA)-mismatched allogeneic HSCT. Methods: We retrospectively collected medical records from 352 consecutive patients with acute myeloid leukemia (n = 214), acute lymphoblastic leukemia (n = 62), or myelodysplastic syndrome (n = 76) in eight centers of Korea between 2005 and 2015. All patients received busulfan-based conditioning without total body irradiation (TBI) and received stem cells from HLA-mismatched donors. Results: In the current study, 5-year overall survival rates of patients receiving low to medium doses of ATG (2.5 to 7.5 mg/kg) were higher than those receiving other doses of ATG (hazard ratio [HR], 0.528; 95% confidence interval [CI], 0.311 to 0.897; p = 0.018). The incidence rates of extensive chronic GVHD (ecGVHD) after administration of low to medium doses of ATG were lower than those after other doses of ATG (HR, 0.447; 95% CI, 0.224 ton 0.889; p = 0.022). Conclusions: The low to medium doses of ATG may be associated with improving survival outcomes and reducing incidence of ecGVHD without enhancing the chances of relapse in patients with acute leukemia or myelodysplastic syndrome undergoing non-TBI-based HLA-mismatched allogeneic HSCT.
참고문헌 (26)
- Korbling M, "Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts", Blood, 85, pp.1659~1665 (1995)
- Sarantopoulos S, "Allogeneic stem-cell transplantation : a T-cell balancing ACT", N Engl J Med, 378, pp.480~482 (2018)
- Theurich S, "Anti-thymocyte globulins for post-transplant graft-versushost disease prophylaxis : a systematic review and meta-analysis", Crit Rev Oncol Hematol, 88, pp.178~186 (2013)
- Zander AR, "Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow", Bone Marrow Transplant, 23, pp.889~893 (1999)
- Kroger N, "Antilymphocyte globulin for prevention of chronic graft-versus-host disease", N Engl J Med, 374, pp.43~53 (2016)
- Remberger M, "A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors", Clin Transplant, 27, pp.E368~E374 (2013)
- Ayuk F, "Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation", Biol Blood Marrow Transplant, 14, pp.913~919 (2008)
- Remberger M, "Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation", Transplantation, 78, pp.122~127 (2004)
- Devillier R, "Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation", Bone Marrow Transplant, 53, pp.431~437 (2018)
- Portier DA, "Anti-thymocyte globulin for conditioning in matched unrelated donor hematopoietic cell transplantation provides comparable outcomes to matched related donor recipients", Bone Marrow Transplant, 47, pp.1513~1519 (2012)
- Cheson BD, "Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia", J Clin Oncol, 21, pp.4642~4649 (2003)
- Przepiorka D, "1994 Consensus conference on acute GVHD grading", Bone Marrow Transplant, 15, pp.825~828 (1995)
- Shulman HM, "Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients", Am J Med, 69, pp.204~217 (1980)
- Zeiser R, "Pathophysiology of chronic graftversus-host disease and therapeutic targets", N Engl J Med, 377, pp.2565~2579 (2017)
- Zeiser R, "Acute graft-versus-host disease : biologic process, prevention, and therapy", N Engl J Med, 377, pp.2167~2179 (2017)
- Bacigalupo A, "Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality : long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation", Biol Blood Marrow Transplant, 12, pp.560~565 (2006)
- Drobyski WR, "Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia", Blood, 83, pp.1980~1987 (1994)
- Finke J, "Standard graftversus-host disease prophylaxis with or without anti-Tcell globulin in haematopoietic cell transplantation from matched unrelated donors : a randomised, open-label, multicentre phase 3 trial", Lancet Oncol, 10, pp.855~864 (2009)
- Socie G, "Chronic graftversus-host disease : long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius", Blood, 117, pp.6375~6382 (2011)
- Bacigalupo A, "Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia : a report from the EBMT-SAA Working Party", Bone Marrow Transplant, 36, pp.947~950 (2005)
- Kim HJ, "Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia", Biol Blood Marrow Transplant, 15, pp.704~717 (2009)
- Basara N, "Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group", Bone Marrow Transplant, 35, pp.1011~1018 (2005)
- Pidala J, "ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation", Biol Blood Marrow Transplant, 17, pp.1237~1244 (2011)
- Baron F, "Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor:a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation", Bone Marrow Transplant, 49, pp.389~396 (2014)
- Devillier R, "Higher doses of antithymocyte globulin (ATG) increase the risk of relapse in acute myeloid leukemia (AML) patients undergoing matched related donor allogeneic transplantation in first complete remission (CR1): an analysis from the acute leukemia working party of EBMT", Blood, 124, pp.729~ (2014)
- Kekre N, "ATG in allogeneic stem cell transplantation : standard of care in 2017? Counterpoint", Blood Adv, 1, pp.573~576 (2017)